The studies involving human participants were reviewed and approved by 1003/2018/SPER/AOUMO – IDO in CLL-”Indoleamina-2,3-diossigenasi come mediatore della tolleranza immunitaria nella leucemia linfatica cronica – IDO”. This evidence concerns the gene IDO1 and B-cell chronic lymphocytic leukemia.